Tolvaptan/Moderate CYP3A4 Inhibitors Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Some medicines may slow down how quickly your liver processes tolvaptan.

What might happen:

The amount of tolvaptan in your blood may increase. If you have just started taking tolvaptan, this may increase the risk of a serious condition called osmotic demyelination syndrome (ODS), which can lead to coma and death. It may also increase your risk of dehydration.

What you should do about this interaction:

Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Let your doctor know right away if you experience any symptoms of ODS such as: trouble speaking, trouble swallowing or feeling like food/liquid is getting stuck when you swallow, drowsiness, confusion, mood changes, trouble controlling body movements, weakness in the arms and/or legs, seizures, loss of consciousness, and/or any other new symptoms. Also let your doctor know if you experience vomiting and/or diarrhea and cannot drink normally and/or if you feel dizzy or faint.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Samsca (tolvaptan) US prescribing information. Otsuka Pharmaceutical Co., Ltd. April, 2018.
  • 2.Jynarque (tolvaptan) tablets US prescribing information. Otsuka America Pharmaceutical, Inc. April, 2018.
  • 3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
  • 4.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.